SATB1 preserves CD4 + T-cell fidelity and establishes Treg function in antitumor immunity
Life Science Alliance · 2026-10 · 9 (10) · e202603763
DOI: 10.26508/lsa.202603763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 14.07.2026. Verfasst von Wooseok Seo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Immune Multicellular System Regulation, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto University Graduate School…. Hauptthemen laut MEDLINE: Matrix Attachment Region Binding Proteins, T-Lymphocytes, Regulatory, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, MEXT | Japan Society for the Promotion of Science, Hori Sciences and Arts Foundation.
Abstract (Originalsprache)
The genome organizer special AT-rich sequence binding protein 1 (SATB1) is critical for the development of T lymphocyte subsets by regulating Foxp3 and Pdcd1 expression. However, its physiological role in mature peripheral T cells has remained obscured by the severe developmental defects caused by early-stage gene knockout models. Here, we used a Thpok-cre driver to specifically delete Satb1 after CD4 lineage commitment. We demonstrate that SATB1 is continuously required to suppress Foxp3 expression in conventional CD4 + T cells; however, this aberrant derepression does not confer Treg suppressive activity. In contrast, FoxP3 + CD25 + Tregs isolated from SATB1-deficient mice exhibit functional defects in immune suppressive function. Although SATB1 deletion does not cause severe global defects in the Treg transcriptome, it disrupts essential FoxP3-mediated gene regulation, resulting in a targeted failure to silence transcripts detrimental to Treg fitness. Physiologically, this Treg-specific functional defect significantly enhances antitumor immunity in a melanoma model. Our findings reveal a dual requirement for SATB1, preserving lineage fidelity by repressing Foxp3 in conventional T cells, while enforcing foundational programming required for Treg suppressive function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cancer Immune Multicellular System Regulation, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto University Graduate School of Medicine, Kyoto, Japan seo.wooseok.2i@kyoto-u.ac.jp.
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Laboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan.
- Laboratory for Immunotherapy, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan.
- Laboratory for Immunogenetics, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan.
- Laboratory for Immune Crosstalk, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan.
ORCID-Profile: Wooseok Seo, Terumi Kohwi-Shigematsu, Hiroyoshi Nishikawa, Ichiro Taniuchi
Förderung
- Japan Science and Technology Agency
- MEXT | Japan Society for the Promotion of Science
- Hori Sciences and Arts Foundation
Zitieren
APA
Seo, W., Zou, C., Shimizu, K., Setoguchi, R., Kakugawa, K., Kohwi-Shigematsu, T., Hori, S., Fujii, S. I., Nishikawa, H., & Taniuchi, I. (2026). SATB1 preserves CD4 + T-cell fidelity and establishes Treg function in antitumor immunity. Life Science Alliance, 9(10), e202603763. https://doi.org/10.26508/lsa.202603763
Vancouver
Seo W, Zou C, Shimizu K, Setoguchi R, Kakugawa K, Kohwi-Shigematsu T, et al. SATB1 preserves CD4 + T-cell fidelity and establishes Treg function in antitumor immunity. Life Science Alliance. 2026;9(10):e202603763. doi:10.26508/lsa.202603763
BibTeX
@article{Seo2026,
author = {Seo, Wooseok and Zou, Chengcheng and Shimizu, Kanako and Setoguchi, Ruka and Kakugawa, Kiyokazu and Kohwi-Shigematsu, Terumi and Hori, Shohei and Fujii, Shin-Ichiro and Nishikawa, Hiroyoshi and Taniuchi, Ichiro},
title = {SATB1 preserves CD4 + T-cell fidelity and establishes Treg function in antitumor immunity},
journal = {Life Science Alliance},
year = {2026},
volume = {9},
number = {10},
pages = {e202603763},
doi = {10.26508/lsa.202603763}
}
EUVIMED